newsfilter
← Latest News
PR Newswire·

Actinium Pharmaceuticals Announces Formation of Scientific Advisory Board Featuring Leading Experts in Oncology and Radiopharmaceutical Development

  • Actinium Pharmaceuticals formed a Scientific Advisory Board of five experts to guide its radioconjugate pipeline across solid tumors & hematologic malignancies.
  • The Board will support the advancement of ATNM-400, a HER3-targeted alpha radiotherapy currently in a first-in-human Phase 1 study for metastatic castration-resistant prostate cancer.
  • Board members include Karim Fizazi (prostate cancer), Sergio A. Giralt (hematologic malignancies), Jason S. Lewis (radiochemistry & molecular imaging), Michael J. Morris (prostate cancer), & Neeta Pandit-Taskar (nuclear medicine).
  • Sandesh Seth, Chairman & CEO, stated the Board's expertise is crucial for optimizing trial designs & accelerating the development of targeted radiotherapies for unmet medical needs.
  • Actinium's pipeline includes ATNM-400 for solid tumors, Actimab-A for AML & MDS in collaboration with the NCI, & conditioning agents Iomab-B & Iomab-ACT.
  • The company holds approximately 250 patents & patent applications related to cyclotron-based production of Ac-225 & differentiated radioconjugates.
Company
Actinium Pharmaceuticals, Inc.
Keywords
Actinium Pharmaceuticals, Inc.